TY - JOUR
T1 - Pharmacological development of the potential adjuvant therapeutic agents against coronavirus disease 2019
AU - Chen, Kuan Hsuan
AU - Wang, Sheng Fan
AU - Wang, Szu Yu
AU - Yang, Yi Ping
AU - Wang, Mong Lien
AU - Chiou, Sih Hwa
AU - Chang, Yuh Lih
N1 - Publisher Copyright:
Copyright © 2020, the Chinese Medical Association.
PY - 2020/9
Y1 - 2020/9
N2 - As the coronavirus disease 2019 (COVID-19, also called severe acute respiratory syndrome coronavirus-2) outbreak accelerates, vigorous and diverse efforts were made in developing treatment strategies. In addition to direct acting agents, increasing evidence showed some potential adjuvant therapies with promising efficacy against COVID-19. These therapies include immunomodulators (i.e. intravenous immunoglobulin, thymosin α‐1, interleukin [IL]-6, tocilizumab, cyclosporine, thalidomide, fingolimod), Chinese medicines (i.e. glycyrrhizin, baicalin, Xuebijing), anti–vascular endothelial growth factors (bevacizumab), estrogen modulating drugs, statins, and nutritional supplements (i.e. vitamins A, B, C, D, E and zinc). This article reviewed the pharmacological development of potential adjuvants for COVID-19 treatment.
AB - As the coronavirus disease 2019 (COVID-19, also called severe acute respiratory syndrome coronavirus-2) outbreak accelerates, vigorous and diverse efforts were made in developing treatment strategies. In addition to direct acting agents, increasing evidence showed some potential adjuvant therapies with promising efficacy against COVID-19. These therapies include immunomodulators (i.e. intravenous immunoglobulin, thymosin α‐1, interleukin [IL]-6, tocilizumab, cyclosporine, thalidomide, fingolimod), Chinese medicines (i.e. glycyrrhizin, baicalin, Xuebijing), anti–vascular endothelial growth factors (bevacizumab), estrogen modulating drugs, statins, and nutritional supplements (i.e. vitamins A, B, C, D, E and zinc). This article reviewed the pharmacological development of potential adjuvants for COVID-19 treatment.
KW - Adjuvant therapy
KW - COVID-19
KW - Pharmacological development
KW - SARS-CoV-2
UR - http://www.scopus.com/inward/record.url?scp=85090614248&partnerID=8YFLogxK
U2 - 10.1097/JCMA.0000000000000375
DO - 10.1097/JCMA.0000000000000375
M3 - Review article
C2 - 32568969
AN - SCOPUS:85090614248
SN - 1726-4901
VL - 83
SP - 817
EP - 821
JO - Journal of the Chinese Medical Association
JF - Journal of the Chinese Medical Association
IS - 9
ER -